Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease
- PMID: 20421689
- PMCID: PMC3098571
- DOI: 10.3233/JAD-2010-100507
Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease
Abstract
Oxidative stress and mitochondrial dysfunction are important features present in Alzheimer's disease (AD). They appear early and contribute to disease progression, both in human postmortem AD brains as well as in transgenic AD mouse brains. For this reason, targeting oxidative stress and mitochondria in AD may lead to the development of promising therapeutic strategies. Several exogenous antioxidant compounds have been tested and found beneficial in transgenic AD mice, such as vitamins and spices. However, their efficacy was much more modest in human trials. More recently, new strategies have been elaborated to promote endogenous antioxidant systems. Different pathways involved in oxidative stress response have been identified. Compounds able to upregulate these pathways are being generated and tested in animal models of AD and in human patients. Upregulation of antioxidant gene expression was beneficial in mice, giving hope for future avenues in the treatment of AD and other neurodegenerative disorders.
Similar articles
-
Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics.Biochim Biophys Acta. 2012 May;1822(5):639-49. doi: 10.1016/j.bbadis.2011.10.011. Epub 2011 Oct 19. Biochim Biophys Acta. 2012. PMID: 22037588 Free PMC article. Review.
-
Mitochondria as a therapeutic target in Alzheimer's disease and diabetes.CNS Neurol Disord Drug Targets. 2009 Dec;8(6):492-511. doi: 10.2174/187152709789824651. CNS Neurol Disord Drug Targets. 2009. PMID: 19702564 Review.
-
Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer's disease.Brain Res Bull. 2012 Feb 10;87(2-3):144-53. doi: 10.1016/j.brainresbull.2011.11.014. Epub 2011 Nov 28. Brain Res Bull. 2012. PMID: 22155297 Review.
-
The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease.J Neurosci. 2011 Nov 2;31(44):15703-15. doi: 10.1523/JNEUROSCI.0552-11.2011. J Neurosci. 2011. PMID: 22049413 Free PMC article.
-
Delineation of Neuroprotective Effects and Possible Benefits of AntioxidantsTherapy for the Treatment of Alzheimer's Diseases by Targeting Mitochondrial-Derived Reactive Oxygen Species: Bench to Bedside.Mol Neurobiol. 2022 Jan;59(1):657-680. doi: 10.1007/s12035-021-02617-1. Epub 2021 Nov 9. Mol Neurobiol. 2022. PMID: 34751889 Review.
Cited by
-
Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.Curr Pharm Des. 2011;17(31):3356-73. doi: 10.2174/138161211798072535. Curr Pharm Des. 2011. PMID: 21902672 Free PMC article. Review.
-
Collaborative Management of Neurocognitive Disorders in Primary Care: Explorations of an Attempt at Culture Change.Perm J. 2017;21:16-027. doi: 10.7812/TPP/16-027. Epub 2017 Jan 6. Perm J. 2017. PMID: 28333613 Free PMC article.
-
Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities.Neurotherapeutics. 2015 Jan;12(1):66-80. doi: 10.1007/s13311-014-0324-8. Neurotherapeutics. 2015. PMID: 25534394 Free PMC article. Review.
-
Synaptic mitochondrial pathology in Alzheimer's disease.Antioxid Redox Signal. 2012 Jun 15;16(12):1467-75. doi: 10.1089/ars.2011.4277. Epub 2011 Dec 15. Antioxid Redox Signal. 2012. PMID: 21942330 Free PMC article. Review.
-
Antioxidant therapies for Alzheimer's disease.Oxid Med Cell Longev. 2012;2012:472932. doi: 10.1155/2012/472932. Epub 2012 Jul 25. Oxid Med Cell Longev. 2012. PMID: 22888398 Free PMC article. Review.
References
-
- Moreira PI, Nunomura A, Nakamura M, Takeda A, Shenk JC, Aliev G, Smith MA, Perry G. Nucleic acid oxidation in Alzheimer disease. Free Radic Biol Med. 2008;44:1493–1505. - PubMed
-
- Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol. 2001;60:759–767. - PubMed
-
- de Leon MJ, Mosconi L, Li J, De Santi S, Yao Y, Tsui WH, Pirraglia E, Rich K, Javier E, Brys M, Glodzik L, Switalski R, Saint Louis LA, Pratico D. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol. 2007;254:1666–1675. - PubMed
-
- Montine TJ, Quinn J, Kaye J, Morrow JD. F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J Mol Neurosci. 2007;33:114–119. - PubMed
-
- Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, Sokolow S, Rosario ER, Gylys KH, Varpetian A, Medina LD, Cummings JL. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology. 2008;71:85–92. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases